clinical trial · NCT00230607
Study of the Effects of Fabrazyme Treatment on Lactation and Infants
Genzyme, a Sanofi Company·phase4·terminated·n = 7
Fabry DiseaseAlpha Galactosidase A Deficiencyagalsidase beta
brief summary
The study was planned for up to 2 years (24 months). Planned full participation for both mother and infant was 24 months, planned full participation of mother and development of infant was 24 months, while planned full participation of mother and no infant participation was 6 months.
started
May 28, 2006
primary completion
Feb 9, 2024
completion
Feb 9, 2024
last updated
Apr 10, 2024
official title
A Multicenter, Multinational Study of the Effects of Fabrazyme (Agalsidase Beta) Treatment on Lactation and Infants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol